Author: Ravi Shankar
Amundi: Launch of the capital increase reserved for employees
Amundi launches a capital increase reserved for employees (under the name We Share Amundi). This capital increase was initially decided on 2 February 2026 under the terms specified below.
This offer reflects Amundi’s desire to involve employees not only in the Company’s development but also in the creation of economic value. This will strengthen the employees’ sense of belonging.
The discount offered to employees will be 30%, as for the previous capital increase reserved for employees.
Eligible employees can subscribe to the offering between 14 September and 25 September 2026 included. The capital increase is scheduled for 22 October 2026 and the newly issued Amundi shares will be listed on Euronext Paris on 26 October 2026.
As a reminder, employees currently own 2.22% of Amundi’s share capital.
The impact of this offering on the net earnings per share should be negligible. The maximum number of Amundi shares to be issued will be capped at 1,000,000 shares (i.e. less than 0.5% of the Company’s share capital and voting rights).
Terms of the capital increase
Issuer
Amundi, a French limited company (société anonyme) with share capital of €515,965,815 and with its offices located at 91-93, Boulevard Pasteur, 75015 Paris, France, registered with the Paris Trade and Companies Registry under number 314 222 902 (the “Company”).
Securities offered
The offering is a capital increase in cash reserved for employees, employees who have taken early retirement and retired employees of Amundi Group companies that are members of the UES Amundi Company Savings Plan (“PEE”) or Amundi’s International Group Savings Plan (“PEGI”). The capital increase will be carried out pursuant to Resolution 27 of the Annual General Meeting of 27 May 2025, without preferential shareholder subscription rights.
The capital increase will be capped at 1,000,000 shares with a par value of €2.50 per share. The newly issued shares will be fully assimilated to existing ordinary shares.
Amundi will request that the newly issued shares under the offering be admitted for trading on Euronext Paris as soon as possible after the capital increase is completed, currently scheduled for 22 October 2026. These shares will be listed on the same line as the existing shares, under ISIN code FR0004125920.Terms of the 2026 offering
We Share Amundi is being made available to employees in France and Amundi Group entities in the following countries: Austria, Czech Republic, Germany, Hong Kong, Ireland, Italy, Japan, Luxembourg, Malaysia, Singapore, Spain, Switzerland, Taiwan and the United Kingdom.
Employees of companies that are members of the PEE or PEGI, with at least three months of employment, whether consecutive or not, between 1 January 2025 and the last day of the subscription period, as well as retired employees in France that have kept assets in the PEE, are eligible to the 2026 offering.
The subscription price is set at 66.63 euros. This subscription price is the average of the share opening price over the 20 trading days between 14 August and 10 September 2026 (included), minus a 30% discount.
Eligible employees can subscribe to the offering between 14 September and 25 September 2026 included.
Shares can be subscribed to via the FCPE (Employment Shareholding Fund) AMUNDI ACTIONNARIAT RELAIS 2026 or FCPE AMUNDI SHARES RELAIS 2026, with the exception of certain countries where shares will be subscribed to directly. Once the capital increase is completed, and following decisions by the funds’ Supervisory Boards and the approval of the French Autorité des Marchés Financiers (AMF), the FCPE AMUNDI ACTIONNARIAT RELAIS 2026 will be merged into the FCPE AMUNDI ACTIONNARIAT, and the FCPE AMUNDI SHARES RELAIS 2026 will be merged into the FCPE AMUNDI SHARES.
The voting rights attached to the shares held via the Funds will be exercised by the Fund’s Supervisory Board. The voting rights attached to the directly-held shares will be exercised by the subscribers.
The shares subscribed to under We Share Amundi will be subject to a five-year lock-up period, unless an early-exit event occurs as described in the PEE or PEGI plan rules. Early-exit events will be adjusted where applicable for certain countries.
An employee can invest up to a maximum of €40,000. This cap is assessed on all the employee shareholding operations of the Crédit Agricole group in which Amundi employees could participate in 2026. Employees may finance their subscription by making voluntary contributions to the plans, up to the annual cap on investments in employee savings plans which is set at 25% of their gross annual compensation. Members of the UES Amundi PEE are also entitled to use their assets held in another specific fund of the PEE.
Should subscription requests exceed the maximum number of shares available under the offering, the smallest subscriptions will be fully honoured while the highest subscriptions will be subject to successive caps until all available shares are subscribed. In France, any cap on subscriptions will first be applied to portions of subscriptions financed by voluntary contributions, then on the subscriptions financed by the transfer of available assets held in another specific fund of the PEE, and finally on the subscriptions financed by the transfer of unavailable assets held in another specific fund of the PEE.
Disclaimer
This press release is for information only and is not a solicitation to subscribe to Amundi shares.
We Share Amundi is strictly reserved to the eligible employees mentioned in this release and shall only be available in countries where such an offer has been registered with the competent local authorities, or the latter has been notified thereof, and/or following the approval of a prospectus by the competent local authorities, or if an exemption has been granted from the obligation to publish a prospectus or to register the offering with the authorities, or to notify the latter thereof.
More generally, We Share Amundi will only be available in countries where all required registration and/or notification procedures have been completed and the necessary authorizations obtained.
Contact
For any questions about We Share Amundi, eligible employees may contact their Head of Human Resources or visit the following website: https://weshare.amundi.com/2026/
***
About Amundi
Amundi, the leading European asset manager, ranking among the top 10 global players1, offers over 200 million investors a complete range of savings and investment solutions in active and passive management, in listed and private assets. Developed for a range of distributors (banks, wealth managers, financial advisors…) as well as for institutional investors and corporates, this offering is enhanced by services and technology tools covering the entire savings value chain. A subsidiary of the Crédit Agricole group and listed on the stock exchange, Amundi currently manages close to €2.6 trillion of assets2.
Its six international investment hubs3, its financial and extra-financial research capabilities and its long-standing commitment to responsible investment make Amundi a leading player in the international asset management landscape.
Thanks to its strong local presence, particularly in Europe and Asia, Amundi offers its clients the expertise and advice of 5,400 professionals across 34 countries.
Amundi, a trusted partner, working every day in the interest of its clients and society
Press contacts:
Natacha Andermahr
Tel. +33 1 76 37 86 05
natacha.andermahr@amundi.com
Corentin Henry
Tel. +33 1 76 36 26 96
corentin.henry@amundi.com
Investor contacts:
Cyril Meilland, CFA
Tel. +33 1 76 32 62 67
cyril.meilland@amundi.com
Thomas Lapeyre
Tel. +33 1 76 33 70 54
thomas.lapeyre@amundi.com
Annabelle Wiriath
Tel. + 33 1 76 32 43 92
annabelle.wiriath@amundi.com
1 Source: IPE “Top 500 Asset Managers” published in June 2026, based on assets under management as at 31/12/2025
2 Amundi data as at 30/06/2026
3 Paris, London, Dublin, Milan, Tokyo and San Antonio (via our strategic partnership with Victory Capital)
Attachment

BROSSARD, Quebec, Sept. 14, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health pathologies using Artificial Intelligence (AI) techniques, announces that the 2026 annual general meeting of shareholders (the “Meeting”) will be held on September 30, 2026, at 10:00 a.m., in person, at Alt Quartier DIX30 Hotel, 6500 de Rome Blvd, 2nd floor, Brossard, QC, J4Y 0B6, for the following purposes:
- To elect the directors of the Corporation;
- To reappoint Raymond Chabot Grant Thornton, LLP, as independent auditor of the Corporation for the ensuing year and to authorize the directors to establish its remuneration; and
- To transact such other business as may properly come before the Meeting.
Attendance and vote
All holders of common shares as of August 26, 2026 are entitled to attend and vote at the Meeting in person or by proxy. Instructions on how to vote can be found in the 2026 Management Information Circular which was mailed on September 3, 2026 and is available on www.sedarplus.com.
The Corporation encourages shareholders to vote early by following the instructions in the meeting materials mailed on September 3, 2026 along with the 2026 Management Information Circular. If you haven’t received your copy, please contact your stockbroker or Computershare Trust Company of Canada at 1-800-564-6253.
Extension of stock warrants exercise period
The Corporation would like to inform the stock warrants holders of the following series of the updated expiry dates.
| Issuance date | Number of stock warrants | Expiry date (original) | Expiry date (extended) |
| October 25, 2024 | 4,603,668 | April 25, 2026 | September 25, 2026 |
| February 5, 2025 | 6,715,369 | August 5, 2026 | June 5, 2027 |
The exercise price remains unchanged at $0.40. For more information you can contact DIAGNOS at info@diagnos.com.
About DIAGNOS
DIAGNOS is a public Canadian corporation dedicated to the early detection of critical eye-related health problems. By developing innovative products based on AI technologies, DIAGNOS’ solutions provide healthcare clinicians with valuable information that refines diagnostic accuracy, streamlines workflows, and improves patient outcome.
Additional information is available at www.diagnos.com and www.sedarplus.com.
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CONTACT: For further information, please contact: Mr. Marc-André Massue CFO and Secretary DIAGNOS Inc. Tel: 450-678-8882 ext. 235

Maranello (Italy), September 14, 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on September 1, 2026, as the third tranche of the multi-year share buyback program of approximately Euro 3.5 billion expected to be executed by 2030 in line with the disclosure made during the 2025 Capital Markets Day (the “Third Tranche”), the additional common shares – reported in aggregate form, on a daily basis – on the Euronext Milan (EXM) and on the New York Stock Exchange (NYSE) as follows:
| EXM | NYSE | Total | ||||||||
| Trading | Number of common shares purchased | Average price per share | Consideration excluding fees | Number of common shares purchased | Average price per share | Consideration excluding fees | Consideration excluding fees | Number of common shares purchased | Average price per share | Consideration excluding fees |
| Date | excluding fees | excluding fees | excluding fees | |||||||
| (d/m/y) | (€) | (€) | ($) | ($) | (€)* | (€)* | (€)* | |||
| 07/09/2026 | 7,000 | 356.1103 | 2,492,772.10 | – | – | – | – | 7,000 | 356.1103 | 2,492,772.10 |
| 08/09/2026 | 7,600 | 352.6602 | 2,680,217.52 | – | – | – | – | 7,600 | 352.6602 | 2,680,217.52 |
| 09/09/2026 | 7,100 | 348.7243 | 2,475,942.53 | 6,207 | 402.7436 | 2,499,829.53 | 2,145,408.11 | 13,307 | 347.2872 | 4,621,350.64 |
| 10/09/2026 | 7,400 | 351.9514 | 2,604,440.36 | – | – | – | – | 7,400 | 351.9514 | 2,604,440.36 |
| 11/09/2026 | 7,400 | 353.7805 | 2,617,975.70 | – | – | – | – | 7,400 | 353.7805 | 2,617,975.70 |
| 36,500 | 352.6397 | 12,871,348.21 | 6,207 | 402.7436 | 2,499,829.53 | 2,145,408.11 | 42,707 | 351.6228 | 15,016,756.32 | |
| Total | ||||||||||
(*) translated at the European Central Bank EUR/USD exchange reference rate as of the date of each purchase
Since the announcement of such Third Tranche till September 11, 2026, the total invested consideration has been:
- Euro 20,807,256.73 for No. 58,800 common shares purchased on the EXM
- USD 7,999,733.07 (Euro 6,887,538.65*) for No. 19,548 common shares purchased on the NYSE.
As of September 11, 2026 the Company held in treasury No. 1,669,152 common shares, net of shares assigned under the Company’s equity incentive plan, corresponding to 0.94% of the then total issued common shares. Including the special voting shares, the Company held in treasury 0.71% of the then total issued share capital.
Since January 5, 2026, start date of the multi-year share buyback program of approximately Euro 3.5 billion announced during the 2025 Capital Markets Day, until September 11, 2026, the Company has purchased a total of 1,779,532 own common shares on EXM and NYSE, including transactions for Sell to Cover, for a total consideration of Euro 538,452,100.59.
A comprehensive overview of the transactions carried out under the buyback program, as well as the details of the above transactions, are available on Ferrari’s corporate website under the Buyback Programs section (https://www.ferrari.com/en-EN/corporate/buyback-programs).
For further information:
Ferrari Media & PR
Email: media@ferrari.com
Attachment

(In accordance with article 5 of Regulation (EU) No 596/2014 on Market Abuse Regulation and article 3(3) of Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No 596/2014 through regulatory technical standards concerning the conditions applicable to buyback programmes and stabilisation measures)
As announced on Thursday 30 July 2026, Ayvens started on Friday 31 July 2026, an ordinary share buyback programme for a maximum amount of EUR 450 million for the purpose of shares cancellation.
Ayvens received all necessary authorisations from supervisory authorities. The share buyback programme will be carried out in accordance with the provisions set out in the EU Regulation n°596/2014 of the European Parliament and of the Council of April 16th 2014, on market abuse, as modified, and its implementing provisions, and within the limits of the authorization granted to Ayvens to purchase shares and cancel such shares pursuant to the 19th and 20th resolutions of the combined General Shareholders’ Meeting held on 13 May 2026. The share buyback is performed on the trading platforms on which Ayvens shares are listed for trading or are traded, including the regulated market of Euronext Paris. The liquidity contract concluded with BNP Paribas Exane has been suspended throughout the buyback period.
Purchases performed from 7 September to 11 September 2026 are described below. As of 11 September 2026, Ayvens has completed 18.13% of its share buyback programme, representing 0.92%1 of its share capital.
Issuer name: Ayvens SA – LEI 969500E7V019H9NP7427
Reference of the financial instrument: ISIN FR0013258662
Period: from 7 September to 11 September 2026
Purchases performed by Ayvens SA during the period
| Issuer’s name | Issuer’s identifying code | Transaction date | Identifying code of financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of shares | Market (MIC code) |
| AYVENS SA | 969500E7V019H9NP7427 | 7-Sep-26 | FR0013258662 | 179,700 | 11.1762 | XPAR |
| AYVENS SA | 969500E7V019H9NP7427 | 7-Sep-26 | FR0013258662 | 93,900 | 11.1648 | CEUX |
| AYVENS SA | 969500E7V019H9NP7427 | 7-Sep-26 | FR0013258662 | 21,100 | 11.1685 | TQEX |
| AYVENS SA | 969500E7V019H9NP7427 | 7-Sep-26 | FR0013258662 | 34,300 | 11.1700 | AQEU |
| AYVENS SA | 969500E7V019H9NP7427 | 8-Sep-26 | FR0013258662 | 186,900 | 10.6467 | XPAR |
| AYVENS SA | 969500E7V019H9NP7427 | 8-Sep-26 | FR0013258662 | 97,550 | 10.6441 | CEUX |
| AYVENS SA | 969500E7V019H9NP7427 | 8-Sep-26 | FR0013258662 | 21,350 | 10.6550 | TQEX |
| AYVENS SA | 969500E7V019H9NP7427 | 8-Sep-26 | FR0013258662 | 34,800 | 10.6516 | AQEU |
| AYVENS SA | 969500E7V019H9NP7427 | 9-Sep-26 | FR0013258662 | 188,900 | 10.5367 | XPAR |
| AYVENS SA | 969500E7V019H9NP7427 | 9-Sep-26 | FR0013258662 | 99,700 | 10.5400 | CEUX |
| AYVENS SA | 969500E7V019H9NP7427 | 9-Sep-26 | FR0013258662 | 21,375 | 10.5759 | TQEX |
| AYVENS SA | 969500E7V019H9NP7427 | 9-Sep-26 | FR0013258662 | 35,000 | 10.5684 | AQEU |
| AYVENS SA | 969500E7V019H9NP7427 | 10-Sep-26 | FR0013258662 | 196,700 | 10.7627 | XPAR |
| AYVENS SA | 969500E7V019H9NP7427 | 10-Sep-26 | FR0013258662 | 102,850 | 10.7483 | CEUX |
| AYVENS SA | 969500E7V019H9NP7427 | 10-Sep-26 | FR0013258662 | 21,850 | 10.7403 | TQEX |
| AYVENS SA | 969500E7V019H9NP7427 | 10-Sep-26 | FR0013258662 | 35,950 | 10.7373 | AQEU |
| AYVENS SA | 969500E7V019H9NP7427 | 11-Sep-26 | FR0013258662 | 205,200 | 10.8049 | XPAR |
| AYVENS SA | 969500E7V019H9NP7427 | 11-Sep-26 | FR0013258662 | 94,463 | 10.7925 | CEUX |
| AYVENS SA | 969500E7V019H9NP7427 | 11-Sep-26 | FR0013258662 | 22,900 | 10.7965 | TQEX |
| AYVENS SA | 969500E7V019H9NP7427 | 11-Sep-26 | FR0013258662 | 35,627 | 10.7982 | AQEU |
| TOTAL | 1,730,115 | 10.7801 |
Aggregated presentation by day and market
| About Ayvens | ||
| Ayvens is a leading global sustainable mobility player committed to making life flow better. We’ve been improving mobility for decades, providing full-service leasing, flexible subscription services, fleet management and multi-mobility solutions to large international corporates, SMEs, professionals and private individuals. | With more than 13,000 employees across 40 countries, Ayvens manages 3.1 million vehicles and the world’s largest multi-brand EV fleet. The company is listed on Compartment A of Euronext Paris (ISIN: FR0013258662; Ticker: AYV). Societe Generale Group is Ayvens’ majority shareholder.
Find out more at ayvens.com |
|
| Press contact | |||
| Elise Boorée Communications Department Tel: +33 (0)6 25 01 24 16 elise.booree@ayvens.com |
|||
1 Ratio between the number of shares repurchased and the 783,862,091 shares comprising the current share capital.
Attachment

- GENFIT’s acquisition of nangibotide, a differentiated late-stage asset, reinforces the Company’s portfolio of innovative therapies addressing high unmet medical needs
- The investigation in Phase 2 is supported by a robust scientific and clinical foundation around the TREM-1 pathway and the asset’s profile:
- Strong knowledge of nangibotide’s biological pathway
- Multiple efficacy signals already observed with nangibotide across three Phase 2 clinical trials in septic shock and COVID-19 subjects, including a statistically significant reduction in mortality in severe COVID-19 and significant improvements in SOFA score from baseline in septic shock
- Overall favorable safety and tolerability profile demonstrated across four clinical trials, with more than 400 subjects exposed to nangibotide, and no meaningful differences versus placebo in safety outcomes
- Nangibotide expected to enter a Phase 2a proof-of-concept study in ACLF in the fourth quarter of 2026, with data readout targeted in 2027
- More details to be disclosed during The Liver Meeting® in Denver, in November 2026
Lille (France), Cambridge (Massachusetts, United States), September 14, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the strengthening of its pipeline through the acquisition of nangibotide in summer 2026, and its plan to investigate nangibotide in a Phase 2 clinical trial for the treatment of Acute-on-Chronic Liver Failure (ACLF).
A clinical and regulatory foundation supporting rapid development
Nangibotide has an extensive human safety package, built on experience from more than 400 subjects across acute inflammatory conditions, supporting the program to move directly into proof-of-concept evaluation in ACLF.
In the post-hoc analysis of Phase 2 clinical trials conducted in septic shock and COVID-19, nangibotide demonstrated multiple efficacy signals, including a statistically significant reduction in mortality.
The existing regulatory and CMC (Chemistry, Manufacturing, and Controls) packages for nangibotide are also well advanced to support rapid clinical development in ACLF, allowing the program to build on an extensive clinical safety database and a mature, well-established manufacturing platform.
Pascal Prigent, CEO of GENFIT, commented: “We believe ACLF represents one of the most significant unmet needs in liver disease. Nangibotide could be a strategic fit for our ACLF portfolio and further reinforces our leadership position in this field. We look forward to advancing the program toward proof of concept.”
Next steps
GENFIT expects to initiate a Phase 2 proof of concept trial in the fourth quarter of 2026, with data available in 2027. The Company will provide more details during The Liver Meeting ® in Denver, in November 2026.
END
ABOUT GENFIT
GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-Chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT’s expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.1 Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT’s largest shareholders, acquiring an 8% stake in the Company’s capital. www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements regarding the development and potential therapeutic profile of nangibotide, the potential role of TREM-1 in Acute-on-Chronic Liver Failure (ACLF), the initiation, design, conduct, timing and results of future clinical trials, including the planned Phase 2a proof-of-concept study in ACLF, the potential clinical benefits, safety profile and therapeutic value of nangibotide, the potential relevance on future clinical investigations of efficacy signals and safety data observed in prior clinical studies conducted in other indications, the expected timing of data readouts, regulatory interactions and future development activities, as well as the Company’s strategic plans and objectives. The use of certain words, such as “believe”, “potential”, “expect”, “target”, “may”, “will”, “should”, “could”, “if” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties relating to the successful integration and development of nangibotide following its acquisition by the Company; the ability to initiate and complete clinical trials within anticipated timelines; uncertainties associated with patient enrollment, site activation and trial execution; the possibility that clinical trial results may not support further development of nangibotide; safety findings that may emerge during future studies and; regulatory requirements, interactions and decisions and manufacturing and supply considerations. No assurance can be given that the planned Phase 2a study will demonstrate efficacy, safety, or clinical benefit, nor that nangibotide will ultimately receive regulatory approval for any indication. Those risks and uncertainties also include those discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Risk Factors and Internal Control” of the Company’s 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers (“AMF”), which is available on GENFIT’s website (www.genfit.fr) and the AMF’s website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.
CONTACTS
GENFIT | Investors
Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 |
jean-christophe.marcoux@genfit.com
Kevin Gardner – Life Science Advisors | kgardner@lifesciadvisors.com
GENFIT | Media
Bruno ARABIAN – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr
Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com
1 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®
Attachment

MONTHLY DECLARATION OF THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
(ARTICLE L233-8II THE COMMERCIAL CODE and 223-16 OF THE GENERAL REGULATIONS OF THE FINANCIAL MARKETS AUTHORITY (AMF))
Charenton-le-Pont, 14th September 2026
MARIE BRIZARD WINE & SPIRITS
ISIN Code: 0000060873
| Situation at: | Total number of shares comprising share capital | Total number of voting rights |
| 31 August 2026 | 111 989 823 | Number of voting rights (1): 203 496 964 Number of exercisable voting rights (2): |
Do the Marie Brizard Wine & Spirits SA by-laws contain a clause requiring disclosure of the crossing of any statutory thresholds in addition to that relating to legal thresholds: yes.
(1) Including treasury shares
(2) After deduction of treasury shares
Attachment

CANTON, Ohio, Sept. 14, 2026 (GLOBE NEWSWIRE) — Concrete Leveling Systems, Inc. (OTC Pink: CLEV) (the “Company”), together with Jericho Associates, Inc. (“Jericho”), its gaming and hospitality division, is pleased to provide shareholders with an update regarding its strategic initiatives.
The Company and Jericho continue to advance several strategic initiatives, including proposed acquisitions, purchase agreements, financing arrangements, due diligence, and applicable regulatory reviews.
Current efforts are focused on completing the documentation and satisfying the financial, transactional, and regulatory requirements associated with these initiatives. The parties are also evaluating additional products and opportunities that may complement and strengthen the broader Jericho platform.
The Company believes Jericho has entered an important stage in the execution of its strategic plan and remains encouraged by the progress achieved to date. The Company and its advisors continue to work with the relevant parties to coordinate the acquisition, financing, transactional, and regulatory components in a disciplined and responsible manner.
The Company appreciates the patience and continued support of its shareholders and looks forward to providing further updates when material developments occur and disclosure is appropriate.
Contact
Jericho Associates – Management Team
rjtass@hotmail.com
Notice Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Statements in this release that are not historical facts, including statements concerning the Company’s or Jericho’s beliefs, plans, expectations, intentions, proposed acquisitions, financing arrangements, regulatory reviews, products, opportunities, or other future events, are forward-looking statements. Words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “may,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words.
Forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied, including uncertainties associated with proposed acquisitions, financing, due diligence, regulatory review, product development, market conditions, and other risks. There can be no assurance that any proposed transaction or initiative will be completed on the terms contemplated, within an anticipated timeframe, or at all.
These forward-looking statements speak only as of the date of this release. Except as required by applicable law, the Company undertakes no obligation to update or revise them. Investors should review all information made publicly available by the Company. Nothing in this release should be interpreted as a projection or guarantee of future revenues, financial condition, operating results, or stock price.

Share buyback program
Aggregated disclosure of transactions in own shares
carried out from September 7 to September 11, 2026
Paris, September 14, 2026,
Pursuant to the authorization granted by the Combined Shareholders’ Meeting held on April 29, 2026, to operate on its shares and in accordance with the regulations relating to share buybacks, Lectra SA (LEI: 9695000KWQEBUDT6IO19) announces below the transactions in its own shares (LSS – FR0000065484) carried out from September 7 to September 11, 2026:
| Issuer Name |
Transaction Date |
Financial Instrument Identifier Code | Total Daily Volume (number of shares) | Daily Volume Weighted Average Acquisition Price (€) | Market (MIC Code) |
| LECTRA | 9/7/2026 | FR0000065484 | 3,803 | 21.6205 | XPAR |
| LECTRA | 9/7/2026 | FR0000065484 | 766 | 21.5787 | AQEU |
| LECTRA | 9/7/2026 | FR0000065484 | 2,701 | 21.6038 | CEUX |
| LECTRA | 9/7/2026 | FR0000065484 | 380 | 21.6005 | TQEX |
| LECTRA | 9/8/2026 | FR0000065484 | 2,759 | 22.1066 | CEUX |
| LECTRA | 9/8/2026 | FR0000065484 | 3,891 | 22.1380 | XPAR |
| LECTRA | 9/8/2026 | FR0000065484 | 789 | 22.1094 | AQEU |
| LECTRA | 9/8/2026 | FR0000065484 | 397 | 22.1315 | TQEX |
| LECTRA | 9/9/2026 | FR0000065484 | 2,956 | 21.6413 | CEUX |
| LECTRA | 9/9/2026 | FR0000065484 | 4,307 | 21.6438 | XPAR |
| LECTRA | 9/9/2026 | FR0000065484 | 810 | 21.6314 | AQEU |
| LECTRA | 9/9/2026 | FR0000065484 | 425 | 21.6205 | TQEX |
| LECTRA | 9/10/2026 | FR0000065484 | 3,015 | 21.5575 | CEUX |
| LECTRA | 9/10/2026 | FR0000065484 | 4,495 | 21.5904 | XPAR |
| LECTRA | 9/10/2026 | FR0000065484 | 811 | 21.5520 | AQEU |
| LECTRA | 9/10/2026 | FR0000065484 | 434 | 21.5191 | TQEX |
| LECTRA | 9/11/2026 | FR0000065484 | 796 | 21.0378 | AQEU |
| LECTRA | 9/11/2026 | FR0000065484 | 4,612 | 21.0558 | XPAR |
| LECTRA | 9/11/2026 | FR0000065484 | 3,040 | 21.0478 | CEUX |
| LECTRA | 9/11/2026 | FR0000065484 | 430 | 21.0316 | TQEX |
| TOTAL | 41,617 | 21.5855 |
| About Lectra
At the forefront of innovation since its founding in 1973, Lectra provides industrial intelligence technology solutions – combining software in SaaS mode, cutting equipment, data, and associated services – to players in the fashion, automotive and furniture industries. Lectra accelerates the transformation and success of its customers in a world in perpetual motion thanks to the key technologies of Industry 4.0: AI, big data, cloud and the Internet of Things. The Group is present in more than one hundred countries. The production sites for its cutting equipment are located in France, China and the United States. Lectra’s 2,800 employees are driven by three core values: being open-minded thinkers, trusted partners and passionate innovators. They all share the same concern for social responsibility, which is one of the pillars of Lectra’s strategy to ensure its sustainable growth and that of its customers. Lectra reported revenues of €507 million in 2025, including €89 million in SaaS revenues. The Company is listed on Euronext, and is included in the CAC Small, CAC Mid & Small, CAC All-Tradable, CAC All Shares, CAC Technology, EN Tech Leaders et ENT PEA-PME 150 indices.
For more information, visit lectra.com. |
Lectra – Registered address: 16–18, rue Chalgrin • 75016 Paris • France
Tel. +33 (0)1 53 64 42 00 – lectra.com
A French Société Anonyme with share capital of €38,063,263. RCS Paris 300 702 305
Attachment

Aggregated presentation by day and by market
| Weekly report on share repurchases from 7th September to 11th September 2026 | ||||||
| Name of the Issuer | Identify code of the Issuer | Transaction day | Identify code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 07/09/2026 | FR0010259150 | 1 587 | 164,3678 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 07/09/2026 | FR0010259150 | 498 | 164,4426 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 08/09/2026 | FR0010259150 | 13 119 | 158,0646 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 08/09/2026 | FR0010259150 | 2 881 | 158,9195 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 09/09/2026 | FR0010259150 | 7 213 | 158,5249 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 09/09/2026 | FR0010259150 | 2 539 | 158,5278 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 09/09/2026 | FR0010259150 | 248 | 158,7573 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 10/09/2026 | FR0010259150 | 0 | 0 | – |
| IPSEN | 549300M6SGDPB4Z94P11 | 11/09/2026 | FR0010259150 | 5 142 | 157,5428 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 11/09/2026 | FR0010259150 | 2 079 | 157,4603 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 11/09/2026 | FR0010259150 | 350 | 157,8571 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 11/09/2026 | FR0010259150 | 103 | 158,0000 | AQEU |
| TOTAL | 35 759 | 158.5202 | ||||
Attachment


